Showing results (231-240 of 288) with videos related to
Sort By:
Pageof 29
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.Expert Review of Hematology|July 26, 2023
Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectivesPeter Valent, Irina Sadovnik, Barbara Peter, et al.Blood|January 9, 2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophilsMichael Kneidinger, Uwe Schmidt, Uwe Rix, et al.Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.Plos Genetics|May 3, 2014
Lifespan extension by methionine restriction requires autophagy-dependent vacuolar acidificationChristoph Ruckenstuhl, Christine Netzberger, Iryna Entfellner, et al.Blood|November 21, 2007
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinibMatthias Mayerhofer, Karoline V Gleixner, Julia Mayerhofer, et al.Developmental Cell|December 19, 2023
Aged intestinal stem cells propagate cell-intrinsic sources of inflammaging in miceMaja C Funk, Jan G Gleixner, Florian Heigwer, et al.Annals of Intensive Care|January 13, 2022
Duration of invasive mechanical ventilation prior to extracorporeal membrane oxygenation is not associated with survival in acute respiratory distress syndrome caused by coronavirus disease 2019Martina Hermann, Daniel Laxar, Christoph Krall, et al.Journal of Clinical Apheresis|September 1, 2016
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failureNina Worel, Gerhard Fritsch, Hermine Agis, et al.Current Cancer Drug Targets|June 11, 2009
Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapyK V Gleixner, M Mayerhofer, A Vales, et al.Pageof 29